Previous 10 | Next 10 |
Koss (KOSS) -14%.C3.ai (AI) -11% on FQ4 earnings release.Stealth BioTherapeutics (MITO) -11%.Express (EXPR) -11% on Q1 earnings releaseFireEye (FEYE) -10% after spins out FireEye Products business to Symphony for $1.2B.Bed Bath & Beyond (BBBY) -10%.PetMed Exp...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Stealth BioTherapeutics Corp. Surges Following Orphan Drug Designation from the European Medicines Agency ” Stealth BioTherapeutics Corp. (NASDAQ: MIT...
Gainers: BriaCell Therapeutics BCTX +151%, Constellation Pharmaceuticals CNST +67%, Soleno Therapeutics SLNO +46%, Stealth BioTherapeutics (MITO) +24%, Aerpio Pharmaceuticals (ARPO) +9%.Losers: iRhythm Technologies IRTC -18%, Progenity (P...
BriaCell Therapeutics (BCTX) +102% after update on the overall survival data of advanced breast cancer patients.Constellation Pharmaceuticals (CNST) +67% on merger agreement with MorphoSys.Stealth BioTherapeutics (MITO) +46% on EMA orphan drug status for elamipretide.AC Immune ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! Let’s get ready for another busy day of trading with a look at the biggest pre-market stock movers for Wednesday. Source: ventdusud / Shutterstock.com But before that. It’s important to m...
Stealth BioTherapeutics (MITO) announces that the European Medicines Agency ((EMA)) has granted orphan drug designation ((ODD)) for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition.Shares up more than 17% post market.ODD is granted to investigational...
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Barth Syndrome PR Newswire BOSTON , June 1, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotec...
Vertex Energy (VTNR) +98% on deal for Shell's Mobile refinery.Moxian (MOXC) +37%.1847 Goedeker (GOED) +22%.SOS Limited (SOS) +14%.Bit Digital (BTBT) +13%.Vir Biotechnology (VIR) +9% as GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization.LAIX (LAIX) +12% on Q1 results...
The following slide deck was published by Stealth BioTherapeutics Corp in conjunction with their 2021 Q1 earnings call. For further details see: Stealth BioTherapeutics Corp 2021 Q1 - Results - Earnings Call Presentation
Stealth BioTherapeutics Corp (MITO) Q1 2021 Earnings Conference Call May 18, 2021, 08:30 AM ET Company Participants Henry Hess - Chief General Counsel Reenie McCarthy - CEO Jim Carr - Chief Clinical Development Officer Brian Blakey - Chief Commercial Officer Rob Weiskopf - CFO Conference Call...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp. Website:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...